In a win for the pharmaceutical industry, the Food and Drug Administration has indefinitely delayed implementing a final rule that would give the agency greater leeway to police off-label marketing.
This marks the second time in the past year the agency has delayed the rule, which was scheduled to go into effect in March, and follows alarm expressed by drug makers that the proposed rule would harm public health and chill “valuable scientific speech.”
About the Author Reprints
One might observe that Commissioner Scott G may be picking his battles – may be, of course is the operative phrase. once again, time will tell.